PUBLIC COMPANY
saveAkero Therapeutics Inc
updated 12d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- A COPD drug from China draws $115M in venture fundingExpedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.biopharma_dive · 6d ago
- Judge orders Apple Tree partner to forfeit oversight of venture fundThe ruling from a Cayman Islands court adds a new wrinkle to an ongoing legal dispute that’s already resulted in a bankruptcy filing — and a bid by general partner Seth Harrison for the firm’s port…biopharma_dive · 28d ago
- Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pillSet to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.biopharma_dive · 28d ago
- STAT+: Akero team, backed by Fairmount, launches new immunology companyFDA approves injectable Leqembi, another post-Makary reversal, and other biotech news from The Readoutstat · 28d ago
- Former Akero team announces new I&I company, Avere, with China drugEverything around China biotech really does seem to be speeding up. On Tuesday, the former executive team behind Akero Therapeutics unveiled a new company, a pipeline drug from China and a reverse…endpoints · 28d ago
comments(0)
5-min edit window · permanent after that